Overview of Allergy-Care

Quick Facts

Property	Description
Active ingredient	Cetirizine Hydrochloride
Form	Oral tablet, liquid syrup, solution
Pharmacological class	Second-generation antihistamine
Common use	Allergy relief (e.g., rhinitis, hives)
Origin	Synthetic

What Type of Medicine is Allergy-Care?

Allergy-Care is a synthetic medicinal product whose active ingredient, Cetirizine Hydrochloride, is precisely classified as a second-generation antihistamine and a peripheral H1-receptor antagonist. This classification signifies that its primary mechanism involves selectively blocking the effects of histamine outside the central nervous system, which is crucial for controlling allergic responses. The drug is clinically recognized for its efficacy in treating various allergic conditions, and its inclusion on global lists of essential medicines further establishes its medical relevance. This recognition confirms that the medicine provides dependable, long-lasting relief from common allergic discomforts.

Composition and Available Forms of Cetirizine Hydrochloride

The sole active ingredient in Allergy-Care is Cetirizine Hydrochloride, supplied as a single active ingredient product. The medicine is a purely synthetic compound, which provides standardization and quality control. For patients, the drug is readily available in multiple oral dosage form(s), including the standard tablet, liquid syrup or solution, and specialized forms often flavored for pediatric patient groups, such as the chewable tablet. This focus on diverse oral preparations ensures flexibility in administration. The chemical structure of Cetirizine is derived from hydroxyzine.

What is the General Purpose of Allergy-Care?

The general purpose of Allergy-Care is to provide effective allergy relief by neutralizing the chemical cascade initiated by histamine. By acting as an antagonist at the peripheral H1 receptors, the medicine helps control the classic manifestations of allergic reactions, including chronic and seasonal allergic rhinitis (hay fever), skin reactions such as urticaria (hives), and associated pruritus (itching). Its selective action ensures that it provides symptomatic control while offering a minimized sedation profile compared to older treatments due to limited crossing of the blood-brain barrier.

Regulatory References

What side effects are possible with Allergy-Care?

Possible side effects and safety information

The official safety profile for Allergy-Care (Cetirizine Hydrochloride) is classified by regulatory authorities based on the frequency and system-organ class involved. Adverse reactions are grouped using the standard frequency framework (e.g., Common, Uncommon, Rare) defined in government documents.

Commonly documented effects (affecting more than 1 in 100 people) primarily involve the nervous and gastrointestinal systems, and include somnolence, fatigue, dry mouth, headache, and dizziness. Uncommon reactions may include agitation and malaise.

Serious and Rare Safety Considerations

The regulatory profile lists rare but clinically significant adverse reactions, categorized as Rare (1/10,000 to < 1/1,000) or Very Rare (< 1/10,000). These include Hypersensitivity reactions, convulsions, and abnormal hepatic function. The most severe reaction documented is Anaphylactic shock, classified as very rare.

Population-Specific Safety Notes

The medicine's clearance may be reduced in certain populations. Official labeling specifies that caution and potential dosage adjustments are necessary for individuals with renal impairment (kidney disease) and for older adults. Furthermore, the drug is contraindicated in individuals with a known hypersensitivity to the active substance or its related compounds, such as hydroxyzine.

Safety notes also include cautions for patients with predisposing factors for urinary retention and those who are epileptic or at risk of convulsions.

Post-marketing surveillance has documented that intense pruritus (itching) and urticaria (hives) may occur upon the cessation of treatment, particularly following long-term use.

Overdose and Emergency Response

Overdose Manifestations and Signs

Official regulatory documents state that an overdose of Cetirizine Hydrochloride primarily manifests as Central Nervous System (CNS) effects. The most frequently documented signs include somnolence, stupor, confusion, fatigue, and headache. Tachycardia (rapid heartbeat) is also listed as a cardiovascular manifestation of excessive ingestion. In rare instances, particularly in children, documented paradoxical effects such as restlessness or agitation may precede CNS depression.

When to Seek Immediate Medical Help

The official guidance strictly mandates that immediate medical attention or contact with emergency services is required in all cases of suspected overdose. This action is necessary because massive exposures carry the potential for severe outcomes, including progression to coma or significant cardiac rhythm changes, as noted in the drug's regulatory profile.

Management and Monitoring Requirements

No specific antidote is known for this compound. Management of an overdose is therefore limited to symptomatic and supportive treatment under medical supervision. Officially described interventions that may be considered include gastric lavage or the administration of activated charcoal to reduce systemic absorption if the ingestion was recent. Intensive monitoring of vital signs, including continuous ECG observation for cardiac function, may be required in severe cases. Furthermore, special considerations for supportive care are noted for the elderly and patients with impaired renal function due to their documented reduced drug clearance.

Therapeutic Uses of Allergy-Care

What Allergy-Care Treats: Main Uses and Benefits

Allergy-Care is indicated to support the management of common allergic conditions. This medication may help address acute symptomatic manifestations of seasonal allergic rhinitis (hay fever), which include symptoms such as a runny nose, sneezing, and itchy, watery eyes. It is also frequently utilized to support the reduction of symptoms associated with perennial allergic rhinitis (year-round allergies).

The therapeutic goal of this medication is to support functional improvement and promote greater overall comfort for individuals affected by persistent or recurrent allergy symptoms, including chronic idiopathic urticaria (hives). By assisting with symptom control, Allergy-Care is intended to help patients maintain daily activities.

Quick Fact: Relief for Nasal Congestion and Itching

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Allergy-Care

The eligibility profile for Allergy-Care (Cetirizine Hydrochloride) is strictly defined by regulatory authorities and prescribes the following conditions for use, restriction, and contraindication.

Populations for Whom Use is Contraindicated

The medicine is contraindicated for patients with known hypersensitivity to the active substance, any excipients, hydroxyzine, or any piperazine derivatives. Use is also contraindicated in patients with severe renal impairment (End-Stage Renal Disease), typically defined as a creatinine clearance ( C Cr) less than 10 mL/min.

Age and Physiological Restrictions

Use is generally not recommended for infants under 6 months of age. Eligibility is restricted for pediatric patients; while liquid forms may be approved from 6 months, tablets are typically approved only for children 6 years and older. Use is not recommended for women who are pregnant or breastfeeding, as the active substance is known to be excreted in human milk.

Condition-Based Limitations

Patients with mild to moderate renal impairment require a mandatory dose adjustment. Use requires regulatory caution in epileptic patients or those at risk of convulsions, and in individuals with predisposing factors for urinary retention (e.g., prostatic hyperplasia).

What should I know about interactions with other medicines?

Interaction Scope

Medicinal product categories with officially documented interaction patterns include Central Nervous System (CNS) Depressants, HIV Protease Inhibitors (e.g., Ritonavir), and Methylxanthines (e.g., Theophylline). A pharmacodynamic interaction occurs with alcohol and other CNS depressants, which may result in additive impairment of alertness or performance, as recognized in regulatory documentation. A pharmacokinetic interaction is formally documented with Ritonavir, co-administration of which increases the extent of cetirizine plasma exposure (AUC) by 42%.

Official Interaction Statements

Official regulatory studies indicate that co-administration of Theophylline results in a minor, non-significant decrease in cetirizine clearance. Conversely, no clinically significant pharmacokinetic interactions have been established with medicines such as Erythromycin, Azithromycin, or Cimetidine. The regulatory text specifies that food does not decrease the extent of absorption of the medicine, though it may delay the time to reach maximum plasma concentration. A multi-day wash-out period is required before allergy skin testing, as the medicine inhibits the histamine response.

Population-Specific and Context Constraints

Regulatory documents note that the clearance of the medicine is reduced in patients with renal or hepatic impairment. This condition increases the vulnerability to any interaction that further reduces clearance or alters exposure. The potential for additive impairment necessitates caution regarding co-administration with alcohol and other CNS-acting substances. The overall interaction profile is defined by these two primary documented interaction types: quantified pharmacokinetic changes and formal pharmacodynamic additive effects.

Mechanism of Action

Primary Mechanism: Blocking Peripheral H1 Receptors

This domain covers the drug's core action as an inverse agonist/antagonist at peripheral Histamine H1 receptors, preventing naturally released histamine from triggering its signaling cascade. This key molecular interference modifies H1-mediated vascular changes, altering capillary permeability and local fluid dynamics.

Secondary Effect: Central Nervous System (CNS) Pathway Modulation

The drug readily crosses the blood-brain barrier, where it blocks H1 receptors critical for the role of central histamine as a major arousal neurotransmitter. This mechanistic interference suppresses central arousal signaling, resulting in CNS depression.

Third Domain: Muscarinic Acetylcholine Receptor Interference

Allergy-Care engages a second set of targets by acting as an antagonist at muscarinic acetylcholine receptors in both central and peripheral pathways. This inhibition of the cholinergic system's regulation of glandular activity alters the rate of secretion.

Dosage and Administration Information

Allergy-Care is administered via two established routes: the primary oral route, covering formulations such as tablets and liquid solutions, and an intravenous (IV) route, which is generally reserved for use in supervised settings for specific acute conditions. The standard oral dosing regimen for adults and adolescents aged 12 years and older is 10 mg once daily, with 10 mg representing the established maximum daily intake for this population.

The medicine is designed for a once-every-24-hours schedule, supporting either continuous management of chronic issues or intermittent use during acute allergic episodes. Oral forms can be taken with or without food, providing flexibility in the timing of intake. Liquid oral preparations, such as syrup, require the use of a calibrated measuring device to ensure dosage precision.

Specific dosage adjustments are required for patients with compromised kidney function. For patients with moderate renal impairment, the oral dose is typically reduced to 5 mg once daily; for severe impairment, the regimen is adjusted to 5 mg once every two days. Similarly, older adults (age 65 years and older) with known renal decline should initiate therapy with a reduced daily dose. Tablet forms are considered unsuitable for children under six years old, as they do not permit the necessary lower dose adjustments required by established guidance.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Drug A

Research has investigated the effect of Drug A on the severity and frequency of X attacks. The majority of studies have focused on adults aged 18 to 65 who have been formally diagnosed with X.

Studies have examined the use of Drug A as a single therapy.
Research is also exploring whether Drug A may be used alongside other established treatments for X.

Some participants in studies have reported a change in symptoms over a short timeframe, and research is examining the duration of observed responses.

Efficacy Data

Monotherapy Studies

The initial research evaluated outcomes associated with Drug A alone over a three-month period. These studies looked at a range of outcomes, including self-reported symptom scores and frequency of X events.

Symptom Frequency: One study with 200 participants observed changes in the average number of monthly X attacks experienced by participants while on Drug A.
Symptom Severity: Researchers have investigated whether Drug A was associated with a change in the intensity of symptoms experienced during an X attack, based on a standardized severity scale.

Combination Therapy Trials

Research has also investigated the outcome of using Drug A in combination with other treatments.

Drug A and Drug B: A study of 150 people with chronic X evaluated whether the combination treatment of Drug A and Drug B was associated with a change in self-reported quality of life over six months.
Comparison to Other Treatments: Studies have also examined Drug A in comparison to another treatment, Drug C. The research evaluated whether there were differences in outcomes observed between the two groups.

Dosing and Administration

Research has examined different starting doses of Drug A in individuals who experience mild to moderate X, focusing on how different doses were associated with changes in symptom presentation. The goal of this research is to describe the observed range of responses at various doses.

Tolerability and Long-Term Observation

Research is ongoing regarding the long-term observation of Drug A. Studies have investigated whether sustained changes in symptoms are maintained over time.

Studies investigating the use of Drug A in individuals with pre-existing kidney conditions have been conducted to observe any potential complications. This research aims to provide data on how Drug A is tolerated across various patient populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Allergy-Care (FAQ)

Q: Is Allergy-Care used for year-round allergies or primarily for seasonal hay fever?

Official product information indicates that Allergy-Care is used for relieving nasal and eye symptoms related to both seasonal (such as hay fever) and perennial (year-round) allergic rhinitis. The drug is also indicated for managing symptoms of chronic idiopathic urticaria, which is commonly known as chronic hives.

Q: How does the mechanism of Allergy-Care differ generally from other common OTC allergy drugs?

Regulatory documents classify this medication as a second-generation antihistamine that is highly selective for peripheral H1 receptors. This classification is typically used to describe medicines designed to have a more focused action outside of the brain and central nervous system. This classification suggests it may be associated with less sedative effects compared to older, first-generation antihistamines, but individual response can vary.

Q: Is Allergy-Care approved for use in treating specific types of food allergies?

Official therapeutic indications for this medicine include seasonal and perennial allergic rhinitis, as well as chronic idiopathic urticaria. Food allergies are not listed as one of the primary official indications in regulatory documentation.

Q: Are reports of dry mouth or dry eyes common with the use of Allergy-Care?

According to the official safety profile, dry mouth is listed as a commonly documented side effect of this medicine. The regulatory text also mentions isolated cases where patients experienced eye accommodation disorders.

Q: Do official sources address whether the side effects of Allergy-Care typically lessen after continued use?

Regulatory safety notes address a specific observation regarding discontinuation, stating that severe itching (pruritus) and hives (urticaria) may occur upon the cessation of long-term use of the medicine. This is a point of information about the withdrawal phase rather than a general rule about side effects lessening over time.

Q: Are there specific warnings about combining Allergy-Care with common cold or flu medications?

Official documents advise caution when combining this drug with other medications that cause drowsiness, which includes certain cold and flu medications as well as sleep aids. This pharmacodynamic interaction may contribute to an additive impairment of alertness or performance, potentially increasing the risk of drowsiness or dizziness.

Q: Is it necessary to avoid certain foods or herbal supplements while taking Allergy-Care?

The official prescribing information states that the medicine can be taken with or without food, as food does not significantly reduce the overall absorption. Regulatory caution notes that if you are taking herbal remedies or supplements that may cause side effects like sleepiness or dry mouth, this should be reviewed by a qualified healthcare professional.

Q: Are there known interactions between Allergy-Care and high blood pressure medications?

Studies and clinical safety data indicate that antihistamines, including the active ingredient in Allergy-Care, are generally considered appropriate for use by people with high blood pressure (hypertension) and stable heart conditions. Research indicates that the drug is generally not associated with common cardiovascular concerns in patients with high blood pressure.

Q: How quickly can a person expect Allergy-Care to begin reducing symptoms?

Research and official information indicate that a person can expect Allergy-Care to begin reducing symptoms generally within twenty to thirty minutes of taking an oral dose. The maximum concentration of the drug in the blood is usually reached in approximately one hour.

Q: Can individuals with a history of heart arrhythmia safely use Allergy-Care?

Official safety reviews suggest the active ingredient has demonstrated no association with cardiac arrhythmias or negative effects on the QT interval when studied at standard doses, unlike some older antihistamines. Information regarding the use of this medicine in individuals with heart conditions should be discussed with a qualified healthcare professional.

Q: Where can a patient find the official full prescribing information or summary of product characteristics for Allergy-Care?

Patients can find the full official documentation, such as the Prescribing Information (PI) or the Summary of Product Characteristics (SmPC), on government health websites. These documents are provided by regulatory bodies like DailyMed (part of the NIH) or the European Medicines Agency (EMA).

Q: Is Allergy-Care available in generic form, and what is its chemical name?

The active ingredient, Cetirizine Hydrochloride, is widely available in a generic formulation. Regulatory bodies acknowledge that these generic forms are bioequivalent to the branded product, offering a lower-cost option.

Q: What is the official caution about taking Allergy-Care with other prescription pain relievers?

The official caution regarding prescription pain relievers specifically addresses a potential interaction with opioid pain medications. Combining the drug with opioids can lead to an increased risk of pronounced drowsiness or dizziness due to an additive effect on the central nervous system.

Q: Is it true that Allergy-Care carries a warning about potentially affecting the ability to drive or operate machinery?

Regulatory labels confirm that because the medicine can cause drowsiness in some individuals, regulatory documents advise caution regarding driving a motor vehicle or operating machinery. This caution is in place until a person knows how the medication specifically affects their alertness and performance.

Q: What inactive ingredients are listed in the official formulation of Allergy-Care tablets?

The official Prescribing Information lists the inactive ingredients included in the tablet formulation. These components generally include substances like lactose monohydrate, corn starch, titanium dioxide, and specific polymers used for coating and binding the tablet.

Q: How is the half-life of Allergy-Care typically described in pharmacokinetic documents?

Pharmacokinetic documents provided to regulatory agencies describe the terminal half-life of the active ingredient in healthy people as approximately 8.3 to 10 hours. This means it takes this amount of time for half the drug to be eliminated from the system.

Q: Does Allergy-Care require dose adjustment for people with mild liver impairment?

Official guidance states that no dose adjustment is needed for patients who have solely mild hepatic (liver) impairment. However, an adjustment is typically recommended for patients who have both hepatic and renal (kidney) impairment.

Q: Is there a maximum time frame for continuous use of Allergy-Care, according to official sources?

Official guidelines support the use of the drug for the chronic management of allergic conditions, and there is no mandatory time limit specified in the standard regulatory labeling. Long-term use is typically reviewed by a qualified healthcare professional.

Q: What is the official guidance for managing a missed dose of Allergy-Care?

According to the official patient information leaflet, the general guidance is that a missed regular dose may be taken as soon as it is remembered that day. However, if it is close to the time for the next dose (usually defined as less than 12 hours), the missed dose should be skipped; regulatory guidance emphasizes that a double dose should not be taken to make up for the missed dose.

How should Allergy-Care be stored and disposed of?

How to Store and Dispose of Allergy-Care?

The storage and disposal of this medicine must strictly follow official regulatory guidelines to maintain drug stability and ensure safety.

Official Storage Requirements

Temperature Control: Store the medicine at controlled room temperature, typically maintained between 20 C and 25 C (68 F and 77 F). Protect the product from freezing and excessive heat.
Environmental Protection: Keep the drug in its original container, tightly closed, and protected from excess moisture and, if specified, light. Do not store in damp areas like bathrooms.
Safety Control: Keep the medicine securely out of the sight and reach of children and pets to prevent accidental ingestion.

Stability and Disposal

Stability After Opening: If the product is a suspension or liquid that requires mixing, discard any unused portion after the specified in-use period (e.g., 14 days) even if it appears stable.
Disposal Guidance: Unused or expired medication should be disposed of via a drug take-back program or mail-back option when available. If these options are not feasible, follow household disposal procedures as directed by regulatory bodies, such as mixing the drug with an undesirable substance before sealing it and discarding it in the household trash.

Allergy-Care